吉西他滨联合奥沙利铂治疗复发或难治性NHL的临床疗效

doi:10.3969/j.issn.1671-7171.2021.12.019

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1118 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨吉西他滨联合奥沙利铂治疗复发或难治性非霍奇金淋巴瘤(NHL)的临床疗效。【方法】回顾性分析2015年7月至2018年7月在本院诊治的86例复发或难治性NHL患者的临床资料,根据治疗方法不同分为对照组(采用长春瑞滨联合奥沙利铂治疗)和观察组(采用吉西他滨联合奥沙利铂治疗),每组43例。比较两组患者临床疗效和不良反应发生率。【结果】治疗后,观察组患者临床总有效率为72.09%(31/43),与对照组的62.79%(27/43)比较,差异无统计学意义(χ²= 0.847,P=0.357);治疗后,两组KPS评分高于治疗前(P<0.05),但两组间比较差异无统计学意义(P>0.05);观察组血小板减少、胃肠道反应、周围神经症状发生率低于对照组(P<0.05);随访12个月,观察组无进展生存率、总生存率分别为58.14%(25/43)、81.40%(35/43),与对照组的55.81%(24/43)、76.74%(33/43)比较,差异均无统计学意义(χ²=0.047,P=0.827;χ²=0.281, P=0.596)。【结论】奥沙利铂联合吉西他滨或长春瑞滨治疗复发或难治性NHL的疗效相当,且前者毒副反应更少。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	阿孜古丽
	毛敏
	木合拜尔·阿布都尔
	安利

关键词 ：淋巴瘤,非霍奇金/药物疗法, 脱氧胞苷/类似物和衍生物, 有机铂化合物/药理学, 治疗结果

Abstract：【Objective】To investigate the effect of gemcitabine combined with oxaliplatin in the treatment of recurrent refractory non-hodgkin's lymphoma (NHL). 【Methods】The clinical data of 86 patients with relapsed refractory NHL in our hospital from July 2015 to July 2018 were retrospectively analyzed. According to the treatment methods, the control group (43 cases) was treated with vinorelbine combined with oxaliplatin, while the observation group (43 cases) was treated with gemcitabine combined with oxaliplatin. The therapeutic effects of the two groups were compared. 【Results】The clinical effective rate of the observation group was 72.09% (31/43), which was higher than that of the control group (62.79%, 27/43). However, the difference was not statistically significant (χ²= 0.847, P=0.357).After treatment, the KPS scores of the two groups were both higher than corresponding KPS scores before treatment (P<0.05), while the difference of post-treatment between the control group and the observation group was not statistically significant (P>0.05).The incidence of thrombocytopenia, gastrointestinal reactions and peripheral nerve symptoms in the observation group was lower than that in the control group (P<0.05).After 12 months of follow-up, the progression-free survival rate and overall survival rate were 58.14% and 81.40% in the study group,respectively. If they were compared to the progression-free survival rate (55.81%) and overall survival rate (76.74%) in the control group, the difference was not statistically significant (χ²=0.047, P=0.827; χ²=0.281, P=0.596). 【Conclusion】Combined use of gemcitabine and oxaliplatin in the treatment of relapsed and refractory NHL has the same effect as vinorelbine combined with oxaliplatin.

Key words： Lymphoma, Non-Hodgkin/DT Deoxycytidine/AA Organoplatinum Compounds/PD Treatment Outcome

收稿日期: 2021-01-18

中图分类号:

R733.4

通讯作者: *E-mail:l49j1ma@163.com

引用本文:

阿孜古丽, 毛敏, 木合拜尔·阿布都尔, 安利. 吉西他滨联合奥沙利铂治疗复发或难治性NHL的临床疗效[J]. 医学临床研究, 2021, 38(12): 1826-1828.
Aziguli, MAO Min, Muhebaier·Abuduer, et al. Effect Analysis of Gemcitabine Combined with Oxaliplatin in the Treatment of Relapsed or Refractory NHL. JOURNAL OF CLINICAL RESEARCH, 2021, 38(12): 1826-1828.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.12.019 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I12/1826